Melanoma is a skin neoplasm that originates from malignant transformation of melanocytes.
It commonly occurs in the extremities of women and on trunk or head and neck in men.
Metastases are via lymphatic and hematogenous routes.
Use of a single-agent temozolomide appears to be an effective alternative to late adjuvant therapy in patients with melanoma if novel treatments, such as targeting and immune therapies, are not available, suggests a recent study.
The PD-1 inhibitor nivolumab continues to yield sustained recurrence-free survival (RFS) benefit over ipilimumab with better tolerability at 4 years in the adjuvant setting for patients with resected stage IIIB–C or IV melanoma, according to the CheckMate 238 trial presented at ESMO 2020.
Current algorithm-based smartphone apps show poor and variable performance in detecting all cases of melanoma or other skin cancer, a systematic review of diagnostic accuracy studies has found. Moreover, the existing assessment processes for awarding the Conformit Europenne (CE) marking for these apps are inadequate for protecting the public.
Use of oestrogen therapy alone appears to contribute to an increased risk of developing cutaneous melanoma, although the addition of progestins may counteract this unfavourable effect, a study has found.
Artificial intelligence (AI) methods appear to be effective for diagnosing melanoma, as the performance of traditional machine learning for the small dataset of melanoma dermoscopic images shows satisfactory results in a recent study.
A complete response to dabrafenib and trametinib treatment in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations leads to greater survival outcomes at 5 years, according to an analysis of data from the COMBI-d* and COMBI-v** trials.
Patients with advanced, unresectable melanoma may derive overall survival (OS) and progression-free survival (PFS) benefits when treated with a nivolumab plus ipilimumab combination or nivolumab alone, according to 4-year results of the phase III CheckMate 067* trial presented at ESMO 2018.
The FDA approval and subsequent use of checkpoint blockade immunotherapy (CBI) and BRAFV600 targeted therapy almost doubled the overall survival (OS) in patients with stage 4 melanoma with brain metastases (MBM), according to a recent US-based study.
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa,
08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.
Use of thyroid hormone therapy does not seem to protect older adults with subclinical hypothyroidism against mortality, but it appears to confer survival benefits to those aged <65 years, results of a study have shown.